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ABSTRACT  
Aims Gene promoter hypermethylation is recognized as an essential early step in carcinogenesis, 
indicating important application areas for DNA methylation analysis in early cancer detection. The 
current study was set out to assess the performance of CADM1, MAL and miR124-2 methylation 
analysis in cervical scrapes for detection of cervical and endometrial cancer. 
 
Methods A series of cervical scrapes of women with cervical (n=79) or endometrial (n=21) cancer, 
CIN3 (n=16) or CIN2 (n= 32), and women without evidence of CIN2 or worse (n=120), was assessed 
for methylation of CADM1, MAL and miR124-2. Methylation analysis was done by the PreCursor-M 
assay, a multiplex quantitative methylation-specific PCR. 
 
Results All samples of women with cervical cancer (79/79, 100%), independent of the histotype, and 
76% (16/21; 95% CI:58.0-94.4) of women with endometrial cancer scored positive for DNA 
methylation of at least one of the three genes. In women without cancer, methylation frequencies 
increased significantly to severity of disease, from 19.2% (23/120; 95% CI:12.1-26.2) in women 
without CIN2 or worse to 37.5% (12/32; 95% CI: 20.7-54.3) and 68.8% (11/16; 95% CI:46.0-91.5) in 
women with CIN2 and CIN3, respectively. Not only overall methylation positivity, but also the 
number of methylated genes increased proportionally to the lesion severity. 
 
Conclusions DNA methylation analysis of CADM1, MAL and miR124-2 in cervical scrapes 
consistently detects cervical cancer and the majority of CIN3 lesions, and has the capacity to broaden 
its use on cervical scrapes through the detection of a substantial subset of endometrial carcinomas.  
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INTRODUCTION 
Cervical cancer is the third most common cancer in women worldwide. In 2008, cervical cancer 
accounted for 9% (529,800) of all new cancer cases and 8% (275,100) of all cancer-related deaths.[1] 
The introduction of cytology-based screening programs, either organized or opportunistic, has 
markedly reduced the incidence and mortality rates of invasive cervical cancer in developed countries. 
Additionally, different studies have described detection of other gynaecological pathologies such as 
endometrial carcinoma by the cytology-based cervical screening program.[2–6] However, the effects 
of cytology-based screening have levelled off. This is mainly due to the suboptimal sensitivity of the 
screening tool (i.e., cytology) for cervical intraepithelial neoplasia (CIN) grades 2 or 3 (CIN2/3) and 
cancer (CIN2/3+), as well a substantial number of women not attending cervical screening. Therefore, 
efforts to improve screening have focused on alternative screening tools to overcome the limitations of 
cytology, and attracting more women into the screening program.  
Over the last years, the importance of primary screening by detection of human papillomavirus (HPV) 
DNA in cervical samples in the prevention of cervical cancer has become clear. A persistent infection 
with a high-risk type of HPV (hrHPV) is necessary for the development of cervical cancer and its 
high-grade precursors.[7] HPV DNA testing appeared substantially more sensitive in detecting 
CIN2/3+ lesions than cytology, providing 50% greater protection against cervical carcinoma and its 
high-grade precursor lesions.[8,9] In addition, HPV DNA testing can also be applied to self-collected 
(cervico-)vaginal specimens, the latter being important to increase the compliance rate in cervical 
screening.[10–12] Yet, HPV DNA testing shows a reduced specificity compared to cytology, since 
many infected women harbour transient viral infections that are not associated with clinically 
meaningful disease. Therefore, it is important to triage hrHPV-positive women for colposcopy to 
identify those women with the highest risk for CIN2/3+  thereby reducing over-referral and 
overtreatment.[7,13,14] DNA methylation analysis of cancer-related genes by quantitative methylation 
specific PCR (qMSP) has emerged as a promising and objective triage tool for early detection of 
cervical neoplasia.[15] Hypermethylation of CpG islands in the promoter regions of tumour 
suppressor genes leads to gene silencing, and is recognized as an essential step in cancer 
development.[16–20] Methylation of cancer-related genes has been described in a variety of 
gynaecological carcinomas, including cervical cancer[15,16,18,21] and endometrial cancer.[22–25] 
We previously showed that methylation-mediated silencing of CADM1 (cell adhesion molecule 1), 
MAL (T-lymphocyte maturation-associated protein) and miR124-2 (micro-RNA124-2) is functionally 
involved in cervical carcinogenesis[17,19,20], and a frequent event detectable in tissue biopsies from 
CIN3 lesions and cervical carcinoma.[18,26] Methylation analysis of the promoter regions of these 
genes by quantitative methylation-specific PCR (qMSP) is valuable in colposcopy triage of hrHPV-
positive women, both when using cervical scrapes[27] and self-collected specimens.[28,29] The bi-
marker panel CADM1/MAL has been validated on hrHPV-positive cervical scrapes collected in a 
population-based screening setting, and showed to be equally discriminatory for CIN3+ as cytology at 
the same specificity level.[27] In a recent prospective randomized trial among non-responders of the 
regular cervical screening program, the bi-marker panel MAL/miR124-2 on hrHPV-positive self-
samples was non-inferior to cytology triage via a physician-taken cervical scrape in detecting 
CIN2+.[29] Of note, methylation levels of these three genes have shown to be related to the severity 
and duration of cervical disease, and are exceptionally increased in cervical cancer.[18,30] As a 
consequence, methylation analysis could be particularly effective in detecting advanced precursor 
lesions (with likely high short-term progression risk) and cervical cancers[15], and could serve as 
complementary tool to cytology triage of hrHPV-positive women to gain a higher reassurance of not 
missing advanced lesions and cervical cancer.[31] These data suggest that cancers are unlikely to 
remain undetected by DNA methylation analysis of cervical scrapes. Yet, no large series of cervical 
scrapes from women with cervical cancer have been evaluated so far, as these are not merely 
encountered in large numbers in a screening setting given the rarity of cervical cancer in the screening 
population.  
In the current study, we evaluated CADM1, MAL and miR124-2 methylation in a large series of 
cervical scrapes from women with various underlying disease grades, including 79 women with 
cervical cancer and 21 with endometrial cancer. We assessed the performance of a multiplex qMSP kit 
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(PreCursor-M, Self-screen B.V., The Netherlands) that allows the combined detection of CADM1, 
MAL and miR124-2 methylation in cervical scrapes.  
 
METHODS 
Study population  
For this study, cervical scrapes of 268 women who participated in population-based cervical screening 
or attended a gynaecological outpatient clinic, were used. Details on the number of cervical scrapes in 
relation to underlying disease category and age of the women are listed in Table 1.Cervical scrapes 
were retrieved from the pathology archive and in case no slides were available, cytological 
preparations were made from diagnostic left over specimen. In this way were able to obtain from 
235/268 (88%) cytology results. Cytology was reported according to the standard classification in the 
Netherlands, i.e., CISOE-A classification, that can be easily translated into Bethesda 
classification[32], in which borderline or mild dyskaryosis (BMD) equals ASC-US/ASC-H/LSIL. 
Presence of hrHPV-DNA was determined by GP5+/6+-PCR.[33] For this study, ethical approval was 
waved, since diagnostic left-over specimens were used that had been anonymized according to the 
Dutch regulations.[34] 
 
Table 1: Overview of cervical scrapes used in this study.  
Disease category Number of scrapes Median age of women (years) 
Cervical carcinoma* 79 48 (range: 23-85) 
Endometrial carcinoma 21 60 (range: 44-87) 
CIN3 16 39 (range: 28-49) 
CIN2 32 40.5 (range: 33-53) 
No evidence of CIN2+ 120 37 (range:18-64) 
*comprising squamous cell carcinoma (SCC; n=62); adenocarcinoma (AdCa; n=12); adenosquamous 
carcinoma (n=2); and undifferentiated carcinoma (n=3). 
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DNA isolation, bisulphite treatment and qMSP methylation analysis 
DNA from cervical scrapes was isolated using the Nucleo-Spin 96 Tissue kit (Macherey-Nagel) and a 
Microlab Star robotic system (Hamilton, Germany) according to manufacturers’ protocol or by 
standard salt-chloroform extraction and isopropanol precipitation.[21,27] Extracted DNA was 
subjected to bisulphite treatment using the EZ DNA Methylation Kit (Zymo Research, USA) as 
described previously.[19,20] DNA methylation analysis of CADM1, MAL and miR124-2 was 
performed by a commercial multiplex qMSP (PreCursor-M, Self-Screen B.V., The Netherlands). 
PreCursor-M uses primers and probes specific for methylated DNA of CADM1, MAL and miR-124-2, 
and methylation-independent β-actin as sample quality control. The multiplex format enables 
simultaneous amplification and detection of the four targets within one reaction.[35] Analyses were 
performed on an ABI 7500 real-time PCR-system (Applied Biosystems, USA). All samples had a Cq 
(Quantification Cycle) value for β-actin <29 to assure sample quality. The target methylation result 
relative to that of a calibrator was calculated as ∆∆Cq ratio for each marker gene (i.e., CADM1, MAL, 
or miR124-2), being a measure for hypermethylation using the 2- ∆∆Cq method.[36] Cervical scrapes 
were scored positive based on preset ∆∆Cq ratio thresholds according to manufacturers’ instructions 
(i.e., validated thresholds that on a validation set of cervical scrapes of hrHPV-positive women gave 
rise to a maximum CIN3+ sensitivity at 70% specificity). 
 
Data and statistical analysis  
For calculations, a sample was considered methylation-positive for a specific target if the ∆∆Cq ratio 
was above the preset threshold of the respective target and overall methylation-positive when at least 
one target was above its preset threshold. The threshold for cytology positivity was BMD. 95% Wald 
confidence intervals (95% CIs) were determined for the proportions of positive samples. The 
proportions of overall methylation-positive samples per disease category (i.e., without evidence of 
CIN2+, CIN2, CIN3 or cervical cancer) were compared using Chi-square analysis. Calculations were 
performed in Microsoft Excel (2010) and SPSS (version 20).  
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RESULTS 
Methylation analysis of cervical scrapes  
A series of 268 cervical scrapes was evaluated (Table 2). DNA methylation of at least one of the three 
loci (CADM1, MAL, and/or miR124-2) was detected in all cervical scrapes of women with cervical 
cancer, independent of the histotype. This percentage was 76.2% for women with endometrial cancer, 
68.8% for CIN3 and 37.5% for CIN2. By comparison, 19.2% of women without evidence of CIN2+ 
had a methylation-positive cervical scrape, comprising 24.7% (19/77;95%CI:15.1-34.3) of the hrHPV-
positive women and 9.3% (4/43;95%CI:6.2-18.0) of the hrHPV-negative women. The frequency of 
methylation positivity increased significantly with the severity of the cervical lesion (Figure 1). 
 
Table 2: CADM1/ MAL/miR124-2 methylation, cytology and hrHPV data of cervical scrapes in 
relation to underlying disease category 
 
 Positive by 
  Methylation Cytology hrHPV 
Disease category n/N % (95%CI) n/N % (95%CI) n/N % (95%CI) 
No evidence of CIN2+ 23/120 19.2 (12.1-26.2) 29/120 24.2 (16.5-31.8) 77/120 64.2 (55.6-72.8) 
CIN2 12/32 37.5 (20.7-54.3) 23/32 71.9 (56.3-87.5) 32/32 100 (100-100) 
CIN3 11/16 68.8 (46.0-91.5) 14/16 87.5 (71.3-100) 16/16 100 (100-100) 
Cervical carcinoma 79/79 100 (100-100) 39/47# 83.0 (72.2-93.7) 73/79 92.4 (86.6-98.3) 
SCC 62/62 100 (100-100) 32/38# 84.2 (72.6-95.8) 60/62 96.8 (92.4-100) 
AdCa 12/12 100 (100-100) 5/6# 83.3 (53.5-100) 9/12 75.0 (50.5-99.5) 
Other* 5/5 100 (100-100) 2/3# 66.7 (13.3-100) 4/5 80.0 (44.9-100) 
Endometrial carcinoma 16/21 76.2 (58.0-94.4) 9/20$ 45.0 ( 23.2-66.8)  4/21 19.0 (2.3-35.8) 
 
*including adenosquamous carcinoma (n=2) and undifferentiated carcinoma (n=3) 
#cytology of 32 women was indeterminate (i.e., 24 SCC, 6 AdCa, 2 other) 
$cytology of 1 woman was indeterminate 
 
Relative contribution of the three targets  
Not only the frequency of methylation positivity, but also the number of markers with a methylation-
positive score increased with the severity of the underlying cervical lesion. Among methylation-
positive cervical scrapes, those of women without evidence of CIN2+ and women with CIN2 lesions 
were mostly single marker positive (78.3%(18/23), and 58.3%(7/12), respectively), whereas the 
majority of women with CIN3 were double marker positive (54.5%;6/11) and those with cervical 
carcinoma triple marker positive (54.4%;43/79). Regarding the two major histotypes of cervical 
carcinoma, the majority of scrapes of women with SCC was triple marker positive (61.3%;38/62), 
whereas AdCa were predominantly double marker positive (66.7%;8/12). All double marker positive 
women with CIN3 and cervical carcinoma were positive for MAL and miR124-2. Among methylation-
positive scrapes of women with endometrial adenocarcinoma, both double (43.8%;7/16), comprising 
various marker combinations) and single marker (56.3%;9/16) positivity were seen, with overall the 
largest contribution by miR124-2 (87.5%;14/16). 
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DISCUSSION 
In this study, we explored the clinical performance of multiplex methylation analysis of CADM1, MAL 
and miR124-2 promoter regions in cervical scrapes, and demonstrated a detection rate of 100% for 
cervical cancer, and 76% (95%CI:58.0-94.4) for endometrial cancer. Our data indicate that 
methylation analysis of CADM1, MAL and miR124-2 in cervical screening would identify all cervical 
carcinomas and holds the detection of endometrial carcinomas as important supplement. The 
standardized assay detects three methylation markers in one single reaction, which requires less 
sample material over separate reactions as has been mainly used in previous studies.[26,28,29] As 
demonstrated in the present study, the three methylation markers have additive value with respect to 
disease detection, in line with previous findings.[26–29] The assay furthermore allows high-
throughput analysis, which is advantageous in screening programs.[35]  
To the best of our knowledge, this is the first study evaluating a large series of cervical scrapes from 
women with cervical or endometrial cancer for DNA methylation of CADM1, MAL and miR124-2. 
The figures corroborate with previous data describing a methylation positivity rate of 100% for 
cervical cancer in smaller sample sets using parallel singleplex assays.[26,27,30] In line with previous 
findings, the number of methylation markers scoring positive, which is inherent to higher methylation 
levels, increased with disease severity.[30] This strongly supports the concept that CIN lesions 
positive with this assay represent more advanced CIN lesions in need of treatment.[15] Based on our 
data, MAL and miR124-2 are the predominant markers for the detection of high-grade cervical and 
endometrial lesions, at the thresholds defined for this assay, with CADM1 adding to reach 100% 
detection rate of cervical cancer. Also HPV-DNA positivity rates in scrapes of women with cervical 
cancer were high in our study. Positivity rates for HPV-DNA in cervical adenocarcinoma tended to be 
lower than SCC, as reported in literature.[37] The lower HPV detection rates in scrapes of cervical 
adenocarcinoma versus SCC may be due to technical aspects, or misdiagnosis of endometrial 
carcinoma as cervical adenocarcinoma. Although comparison of the methylation test to cytology is 
skewed as cancer patients were mainly referred because of abnormal cytology, it was noted that  
scrapes with normal cytology (n=8) of women with cervical cancer were detected by the methylation 
assay. The detection of a substantial subset of endometrial carcinomas is an important supplement of 
methylation analysis of cervical scrapes. The addition of other methylation markers[25] or other 
molecular markers such as tumour-specific mutations[38] might improve the overall diagnostic 
accuracy for gynaecologic malignancies in the future. 
At present, the methylation assay is proposed to be used as triage test for HPV-positive women, with 
clinical utility in detection of CIN2+/3+ shown for both hrHPV-positive cervical scrapes[27,31] and 
hrHPV-positive self-collected specimens.[28,29] Current findings also suggest the prospect of the 
methylation assay as primary cervical screening tool. Particularly the high sensitivity for cancer opens 
the way to a direct screen and treatment approach. Especially in low and middle income countries, 
where cervical screening is hard to implement and follow-up rates are low, this approach might be 
attractive.  
In conclusion, multiplex DNA methylation analysis of the CADM1, MAL and miR124-2 loci in 
cervical scrapes consistently identifies cervical cancer and the majority of CIN3 lesions, and has the 
capacity to broaden its use on cervical scrapes through the detection of a substantial subset of 
endometrial carcinoma. As such, it is a promising step toward a broadly applicable screening 
methodology and lays the foundation for a new generation of molecular screening. 
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Key messages 
• Methylation analysis of CADM1, MAL and miR124-2  in cervical scrapes consistently detects 
cervical cancer and the majority of CIN3 lesions. 
• Overall methylation positivity and the number of methylated genes in cervical scrapes increase 
proportionally with underlying disease severity. 
• DNA methylation analysis of CADM1, MAL and miR124-2 in cervical scrapes has the capacity to 
broaden its use through the detection of a substantial subset of endometrial carcinomas.  
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FIGURE 
 
Figure 1: CADM1, MAL and miR124-2 methylation in cervical scrapes in relation to underlying 
lesion type.  
 
Shown is the fraction of methylation positive cases as determined by multiplex qMSP (y-axis) in 
relation to the lesion type (x-axis). 
